Reportedly, Merck & Co., Inc. (MRK) has developed a hexavalent combination vaccine Vaxelis™ in partnership with Sanofi Pasteur, the global vaccines business unit of Sanofi. Vaxelis will be widely available in the U.S. via traditional private and public channels, including directly from Sanofi Pasteur via vaccineshoppe.com.
“As the first six-in-one vaccine in the U.S., Vaxelis is now available to help protect infants and children against diseases caused by six infectious agents. We are proud to offer this vaccine to healthcare professionals and the patients they serve. Studies have shown that combination vaccines may help reduce the shot burden and improve coverage rates and timeliness.” stated Elaine O’Hara, Head of Sanofi Pasteur Commercial Operations North America.
Vaxelis is the only and first hexavalent (six-in-one) combination vaccine given to protect a child from getting tetanus (lockjaw), diphtheria, polio, Hib (Haemophilus influenza type b), pertussis (whooping cough), and hepatitis B. The vaccine is given to kids from 6 weeks through 4 years of age and is given as 3 shots at specified intervals.
The U.S. Centers for Disease Control and Prevention’s Advisory Committee included Vaxelis as a combination vaccine option in the CDC’s recommended Child and Adolescent Immunization Schedule on February 11, 2021.
Joanne Monahan, senior vice president, U.S. Vaccines, Merck, stated “Given the potential to reduce the number of shots by as many as three in the first six months of life, as compared to pentavalent vaccines plus hepatitis B or Haemophilus influenzae type b vaccines, Vaxelis represents an important option for healthcare professionals and parents,”, “Merck and Sanofi have been in contact with the major insurers and the appropriate pricing publications to notify them of the availability of Vaxelis, and we look forward to working with payers and providers to deliver this novel hexavalent vaccine to help protect age-appropriate children. This news should also help to remind providers and parents of the importance of continuing routine vaccinations and recommended well visits.”
Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at the leading edge of research. Merck has the industry’s largest immuno-oncology clinical research program. To learn more about Merck (MRK) and to track its ongoing progress please visit the Vista Partners Merck Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research. Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
june2(3)
